Chronological alterations in de novo malignancies after living-donor liver transplantation: A cohort study of 1781 recipients using annual comparisons of standardized incidence ratios.
incidence
liver transplantation
living donors
lymphoproliferative disorders
neoplasms
Journal
Journal of hepato-biliary-pancreatic sciences
ISSN: 1868-6982
Titre abrégé: J Hepatobiliary Pancreat Sci
Pays: Japan
ID NLM: 101528587
Informations de publication
Date de publication:
06 Jun 2024
06 Jun 2024
Historique:
medline:
7
6
2024
pubmed:
7
6
2024
entrez:
7
6
2024
Statut:
aheadofprint
Résumé
De novo malignancies (DNMs) are a major adverse event after solid organ transplantation; however, their characteristics and recent trends after living-donor liver transplantation (LDLT) remain unclear. We retrospectively reviewed 1781 primary LDLT recipients (1990-2020) and annually calculated standardized incidence ratios (SIRs) of DNMs compared to the age-adjusted Japanese general population. After 21 845 person-years follow-up, 153 DNM lesions (8.6%) were identified in 131 patients (7.4%). The incidence was 0.007 person-years. DNMs included 81 post-transplant lymphoproliferative disorders (PTLDs), 14 colorectal, 12 lung, and 12 gastric cancers, and so on. Comorbid DNMs significantly worsened recipient survival than those without (p < .001). The 5- and 10-year recipient survival after DNM diagnosis were 65% and 58%, respectively. Notably, SIR DNM development after LDLT was significantly higher than in the general population due to higher PTLD incidence (1993-1998), but once became equivalent (2005-2013), then significantly increased again (2014-2019) due to recent recipient aging and resultant increase in solid cancers.
Sections du résumé
BACKGROUND
BACKGROUND
De novo malignancies (DNMs) are a major adverse event after solid organ transplantation; however, their characteristics and recent trends after living-donor liver transplantation (LDLT) remain unclear.
METHODS
METHODS
We retrospectively reviewed 1781 primary LDLT recipients (1990-2020) and annually calculated standardized incidence ratios (SIRs) of DNMs compared to the age-adjusted Japanese general population.
RESULTS
RESULTS
After 21 845 person-years follow-up, 153 DNM lesions (8.6%) were identified in 131 patients (7.4%). The incidence was 0.007 person-years. DNMs included 81 post-transplant lymphoproliferative disorders (PTLDs), 14 colorectal, 12 lung, and 12 gastric cancers, and so on. Comorbid DNMs significantly worsened recipient survival than those without (p < .001). The 5- and 10-year recipient survival after DNM diagnosis were 65% and 58%, respectively. Notably, SIR
CONCLUSION
CONCLUSIONS
DNM development after LDLT was significantly higher than in the general population due to higher PTLD incidence (1993-1998), but once became equivalent (2005-2013), then significantly increased again (2014-2019) due to recent recipient aging and resultant increase in solid cancers.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Subventions
Organisme : Shimadzu
Informations de copyright
© 2024 The Author(s). Journal of Hepato‐Biliary‐Pancreatic Sciences published by John Wiley & Sons Australia, Ltd on behalf of Japanese Society of Hepato‐Biliary‐Pancreatic Surgery.
Références
Engels EA, Pfeiffer RM, Fraumeni JF Jr, Kasiske BL, Israni AK, Snyder JJ, et al. Spectrum of cancer risk among US solid organ transplant recipients. JAMA. 2011;306:1891–1901.
Adami J, Gabel H, Lindelof B, Ekstrom K, Rydh B, Glimelius B, et al. Cancer risk following organ transplantation: a nationwide cohort study in Sweden. Br J Cancer. 2003;89:1221–1227.
Kasiske BL, Snyder JJ, Gilbertson DT, Wang C. Cancer after kidney transplantation in the United States. Am J Transplant. 2004;4:905–913.
Vajdic CM, McDonald SP, McCredie MR, van Leeuwen MT, Stewart JH, Law M, et al. Cancer incidence before and after kidney transplantation. JAMA. 2006;296:2823–2831.
Villeneuve PJ, Schaubel DE, Fenton SS, Shepherd FA, Jiang Y, Mao Y. Cancer incidence among Canadian kidney transplant recipients. Am J Transplant. 2007;7:941–948.
Collett D, Mumford L, Banner NR, Neuberger J, Watson C. Comparison of the incidence of malignancy in recipients of different types of organ: a UK registry audit. Am J Transplant. 2010;10:1889–1896.
Pilleron S, Sarfati D, Janssen‐Heijnen M, Vignat J, Ferlay J, Bray F, et al. Global cancer incidence in older adults, 2012 and 2035: a population‐based study. Int J Cancer. 2019;144:49–58.
Umeshita K, Eguchi S, Egawa H, Haga H, Kasahara M, Kokudo N, et al. Liver transplantation in Japan: registry by the Japanese Liver Transplantation Society. Hepatol Res. 2019;49:964–980.
Tajima T, Hata K, Haga H, Nishikori M, Umeda K, Kusakabe J, et al. Post‐transplant lymphoproliferative disorders after liver transplantation: a retrospective cohort study including 1954 transplants. Liver Transpl. 2021;27:1165–1180.
Tajima T, Hata K, Kusakabe J, Miyauchi H, Yurugi K, Hishida R, et al. The impact of human leukocyte antigen mismatch on recipient outcomes in living‐donor liver transplantation. Liver Transpl. 2022;28:1588–1602.
Kaneko J, Sugawara Y, Tamura S, Aoki T, Sakamoto Y, Hasegawa K, et al. De novo malignancies after adult‐to‐adult living‐donor liver transplantation with a malignancy surveillance program: comparison with a Japanese population‐based study. Transplantation. 2013;95:1142–1147.
Miyazaki T, Sato S, Kondo T, Kusaka M, Gotoh M, Saiki Y, et al. National survey of de novo malignancy after solid organ transplantation in Japan. Surg Today. 2018;48:618–624.
Takada Y, Uemoto S. Liver transplantation for hepatocellular carcinoma: the Kyoto experience. J Hepatobiliary Pancreat Sci. 2010;17:527–532.
Tajima T, Hata K, Haga H, Kusakabe J, Kageyama S, Yurugi K, et al. Risk factors for antibody‐mediated rejection in ABO blood‐type incompatible and donor‐specific antibody‐positive liver transplantation. Liver Transpl. 2023;29:711–723.
Egawa H, Umeshita K, Uemoto S. Optimal dosage regimen for rituximab in ABO‐incompatible living donor liver transplantation. J Hepatobiliary Pancreat Sci. 2017;24:89–94.
Demetris A, Adams D, Bellamy C, Blakolmer K, Clouston A, Dhillon AP, et al. Update of the international Banff schema for liver allograft rejection: working recommendations for the histopathologic staging and reporting of chronic rejection. An international panel. Hepatology. 2000;31:792–799.
Demetris AJ, Bellamy C, Hubscher SG, O'Leary J, Randhawa PS, Feng S, et al. 2016 comprehensive update of the Banff Working Group on Liver Allograft Pathology: introduction of antibody‐mediated rejection. Am J Transplant. 2016;16:2816–2835.
Cancer Statistics. Cancer Information Service, National Cancer Center, Japan (National Cancer Registry, Ministry of Health, Labour and Welfare and Monitoring of Cancer Incidence in Japan [MCIJ]). Available from: https://ganjoho.jp/reg_stat/statistics/data/dl/index.html#a14. Accessed Mar 24, 2024.
Rodriguez‐Peralvarez M, Colmenero J, Gonzalez A, Gastaca M, Curell A, Caballero‐Marcos A, et al. Cumulative exposure to tacrolimus and incidence of cancer after liver transplantation. Am J Transplant. 2022;22:1671–1682.
Herrero JI. De novo malignancies following liver transplantation: impact and recommendations. Liver Transpl. 2009;15 Suppl 2:S90–S94.
Jiang Y, Villeneuve PJ, Fenton SS, Schaubel DE, Lilly L, Mao Y. Liver transplantation and subsequent risk of cancer: findings from a Canadian cohort study. Liver Transpl. 2008;14:1588–1597.
Schrem H, Kurok M, Kaltenborn A, Vogel A, Walter U, Zachau L, et al. Incidence and long‐term risk of de novo malignancies after liver transplantation with implications for prevention and detection. Liver Transpl. 2013;19:1252–1261.
Seree O, Altieri M, Guillaume E, De Mil R, Lobbedez T, Robinson P, et al. Longterm risk of solid organ de novo malignancies after liver transplantation: a French National Study on 11,226 patients. Liver Transpl. 2018;24:1425–1436.
Park B, Yoon J, Choi D, Kim HJ, Jung YK, Kwon OJ, et al. De novo cancer incidence after kidney and liver transplantation: results from a nationwide population based data. Sci Rep. 2019;9:17202.
Yeh CC, Khan A, Muo CH, Yang HR, Li PC, Chang CH, et al. De novo malignancy after heart, kidney, and liver transplant: a nationwide study in Taiwan. Exp Clin Transplant. 2020;18:224–233.
Staatz CE, Tett SE. Clinical pharmacokinetics and pharmacodynamics of tacrolimus in solid organ transplantation. Clin Pharmacokinet. 2004;43:623–653.
Colmenero J, Tabrizian P, Bhangui P, Pinato DJ, Rodriguez‐Peralvarez ML, Sapisochin G, et al. De novo malignancy after liver transplantation: risk assessment, prevention, and management‐guidelines from the ILTS‐SETH consensus conference. Transplantation. 2022;106:e30–e45.
Hashiguchi Y, Muro K, Saito Y, Ito Y, Ajioka Y, Hamaguchi T, et al. Japanese Society for Cancer of the Colon and Rectum (JSCCR) guidelines 2019 for the treatment of colorectal cancer. Int J Clin Oncol. 2020;25:1–42.
Ueno P, Felipe C, Ferreira A, Cristelli M, Viana L, Mansur J, et al. Wound healing complications in kidney transplant recipients receiving everolimus. Transplantation. 2017;101:844–850.
Kubota T, Hata K, Sozu T, Ueda Y, Hirao H, Okamura Y, et al. Impact of donor age on recipient survival in adult‐to‐adult living‐donor liver transplantation. Ann Surg. 2018;267:1126–1133.